There’s nothing better than seeing good news in the early morning email alerts I have set up on cancer research!
Today, it was the turn of Astellas and Medivation to announce the results of the TERRAIN study, which is a primarily European phase 2 trial that began in March 2011 in the prechemotherapy setting for castrate resistant prostate cancer (CRPC). The trial met its primary endpoint of progression free survival (PFS).
Why is this an important landmark in CRPC and what does the initial data show?
Subscribers can login to read more or you can purchase access by clicking on the blue icon at the end of the post.